IQVIA (NYSE:IQV) Price Target Lowered to $223.00 at Robert W. Baird

IQVIA (NYSE:IQV) had its price objective trimmed by Robert W. Baird from $256.00 to $223.00 in a research report sent to investors on Friday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Several other brokerages also recently commented on IQV. Truist Financial reduced their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Barclays decreased their price objective on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a report on Tuesday, October 15th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Royal Bank of Canada assumed coverage on shares of IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $261.24.

IQVIA Stock Up 1.6 %

Shares of NYSE:IQV traded up $3.34 during trading on Friday, hitting $209.16. 1,791,887 shares of the company were exchanged, compared to its average volume of 1,125,496. IQVIA has a fifty-two week low of $181.03 and a fifty-two week high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.85 and a debt-to-equity ratio of 1.76. The firm has a fifty day moving average price of $234.31 and a two-hundred day moving average price of $229.74. The stock has a market cap of $38.13 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.01 and a beta of 1.51.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

Institutional Trading of IQVIA

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Covestor Ltd increased its stake in shares of IQVIA by 34.4% in the third quarter. Covestor Ltd now owns 246 shares of the medical research company’s stock valued at $59,000 after buying an additional 63 shares during the period. Atria Investments Inc raised its stake in shares of IQVIA by 6.6% during the third quarter. Atria Investments Inc now owns 20,404 shares of the medical research company’s stock valued at $4,835,000 after acquiring an additional 1,261 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV acquired a new stake in shares of IQVIA in the third quarter valued at about $224,000. Carmel Capital Partners LLC increased its position in IQVIA by 10.5% during the 3rd quarter. Carmel Capital Partners LLC now owns 7,558 shares of the medical research company’s stock valued at $1,791,000 after purchasing an additional 721 shares during the period. Finally, Lindbrook Capital LLC raised its stake in IQVIA by 8.0% during the third quarter. Lindbrook Capital LLC now owns 923 shares of the medical research company’s stock worth $219,000 after buying an additional 68 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.